

In the Claims:

Please amend Claim 39 as follows:

39. (Once amended) An isolated polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127);
- (b) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127); or
- ~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide; or~~
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209263,  
wherein said polypeptide is capable of inhibiting neoplastic cell growth.

40. (Once amended) The isolated polypeptide of Claim 39 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127);
- (b) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide;
- ~~(e)(c)~~ (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127); or
- ~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide; or~~
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209263,  
wherein said polypeptide is capable of inhibiting neoplastic cell growth.

41. (Once amended) The isolated polypeptide of Claim 39 having at least 90% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127);
  - (b) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide;
  - (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127); or
  - (d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide; or~~
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209263, wherein said polypeptide is capable of inhibiting neoplastic cell growth.

- C10
42. (Once amended) The isolated polypeptide of Claim 39 having at least 95% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127);
  - (b) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide;
  - (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127); or
  - (d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide; or~~
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209263, wherein said polypeptide is capable of inhibiting neoplastic cell growth.

43. (Once amended) The isolated polypeptide of Claim 39 having at least 99% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127);
  - (b) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide,
  - (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127); or
  - (d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide; or~~
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209263,  
wherein said polypeptide is capable of inhibiting neoplastic cell growth.
44. (Once amended) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127);
  - (b) the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide;
  - (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127); or
  - (d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide; or~~
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209263.
45. (Previously added) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127).

46. (Previously added) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 46 (SEQ ID NO:127), lacking its associated signal peptide.
47. (Previously added) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 46 (SEQ ID NO:127).
48. Cancel.
49. (Previously added) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209263.
- C10* 50. (Previously added) A chimeric polypeptide comprising a polypeptide according to Claim 39 fused to a heterologous polypeptide.
51. (Previously added) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.
-